Sexually Transmitted Diseases (STDs) spread primarily through person-to-person sexual contacts. Varied testing technologies used for the identification and analysis of the STD contracted comprise the definition of ‘diagnostic testing of STDs’. The location where diagnostic tests are delivered i.e. in the laboratories or at the point-of-care (POC) also encompasses the definition for ‘diagnostic testing of STDs’. The Medicines and Healthcare Products Regulatory Agency (MHRA) defines POC testing as ‘any analytical test performed for a patient by a healthcare professional outside the conventional laboratory setting’.
Undiagnosed (that often results in untreated cases) STDs can have critical implications for reproductive, maternal and newborn health. For instance, 10% - 15% of women with untreated Chlamydia infection may develop symptomatic pelvic inflammatory disease (PID); progression of ~10% - 15% of PID cases lead to tubal factor infertility. Human Papilloma Virus (HPV) is the causative agent for ~99% of cervical cancers in women. Globally, HPV infection results in ~500,000 cases of cervical cancer and ~300,000 cervical cancer deaths per year. Undiagnosed and untreated STDs such as Syphilis lead to Congenital Syphilis - that results in preterm labor with associated risks of pre-term birth, low birth weight, blindness and death of the neonate. Globally, over 1 million cases of Syphilis occur among pregnant women and a majority proportion of these were untreated or inadequately treated. Unless testing and treatment of Syphilis in pregnancy are readily available, over 50% of the pregnancies in women with Syphilis will result in adverse outcomes as stated above.
Prenatal transmission of Herpes Simplex Virus (HSV) infection is associated with a high risk of neurological problems and death. Undiagnosed and untreated STDs also increase the risk of both acquisition and transmission of Human Immunodeficiency Virus (HIV), by a factor of up to two- to three-fold. Timely diagnosis of STDs is thus imperative for prevention of transmission, control and reducing the risk of incurable and fatal STD infections.
STDs can broadly be categorized as STDs of the developed regions and STDs of the poor/developing regions. As STDs namely Chlamydia, Gonorrhea and P&S Syphilis are more prevalent in North America and Europe, these developed regions have a higher market share in terms of testing volume. While Chancroid is non-existent in these developed region, for instance, there are only about 8 - 10 cases in North America. Moreover occurrence of these Chancroid cases in North America or Europe is solely a result of acquiring this infection i.e. travelling to the Rest of the World regions. As many of the viral STDs trace origin in the poor/developing regions such as the RoW; these regions have garnered a higher market share in terms of testing volume of STDs such as HIV, HSV and Chancroid.
Laboratory testing is of high significance for diagnostic testing of STDs; as although many Point-Of-Care (POC) tests are available for all STDs, some STDs cannot be diagnosed by POC methods and devices. For example, HSV, Low-risk HPV and Chancroid that clinically manifest as warts, require physical examination by laboratory experts. Also many of the POC methods and devices are not approved by the regulatory authorities such as the U.S. FDA; many of these fail to qualify the specificity and sensitivity norms prescribed by the regulatory authorities. Hence laboratory testing for diagnosis of STDs is considered reliable and the universally accepted diagnostic testing method.
Sexually transmitted diseases (STDs), also called sexually transmitted infections (STIs) or venereal diseases (VDs), are caused by over 30 different viruses, bacteria, and parasites and are predominantly spread by sexual contact and sometimes by non-sexual means. Diagnostic testing for STDs becomes especially essential since they can have serious consequences on sexual and reproductive health - ranging from infertility and pelvic inflammatory diseases to AIDS and cervical cancer.
According to the WHO, over one million people around the world acquire an STD every day and STIs are among the top five disease categories for which adults seek medical care. The market for diagnostic testing of STDs has gained significance owing to the rising risks of undiagnosed and ultimately untreated cases of STIs.
The primary goal of this research report is to help readers understand the overall structure of the diagnostic testing of STDs market, its elements, factors that drive and restrict the growth of the market, and strategies adopted by various players to gain a dominant market share, observe and track key trends, study the behavior of consumers, and provide an analysis of the opportunities present in the market for diagnostic testing of STDs.
Overview of the global diagnostic testing of STDs market
The market value of diagnostic testing of STDs was US$65.9 billion in 2012 and, registering a healthy CAGR of 8.1% during the forecast period of 2013 to 2019, is estimated to be worth US$108.5 billion by 2019.
The diagnostic testing of STDs market is largely driven by the growing incidences of STDs. Given this worrying fact, governments around the globe have begun implementing screening programs to diagnose STDs at an early stage and begin appropriate treatment. National screening programs are a great opportunity for POC and laboratory test providers, especially in diagnostic testing of STDs markets in the Asia-Pacific and Rest of the World regions. In addition, favorable reimbursements aimed at STD testing have also been issued, boosting the market for diagnostic testing of STDs.
On the other hand, the stigma associated with voluntary testing or client-initiated counseling and testing (CICT) of STDS is a major challenge in most countries even today. The irony is that a significant proportion of STD-infected patients are in regions that either do not have sufficient infrastructure for diagnostic testing of STDs or have no encouragement to get tested without being shamed. Apart from this, the presence of strict regulatory compliances for existing and new market players is restricting the growth of the diagnostic testing for STDs market.
Presently, North America and Europe dominate the global market owing to increased prevalence of STDs such as herpes simplex virus (HSV), chancroid, human papilloma virus (HPV), P&S syphilis, human immunodeficiency virus (HIV), gonorrhea, and chlamydia.
Companies mentioned in the research report
The key players featured in diagnostic testing for STDs market report are bioMerieux, Hologic, Inc. (Gen-Probe), Becton Dickinson & Company, Roche Holdings AG, Alere, Inc., and Danaher Corporation (Beckman Coulter).
- Segmentation based on STD type
- Herpes Simplex Virus (HSV) testing
- Chancroid testing
- Human Papilloma Virus (HPV) testing
- P&S Syphilis testing
- Human Immunodeficiency Virus (HIV) testing
- Gonorrhea testing
- Chlamydia testing
Segmentation based on location
- Point-of-Care (POC) Testing
- Laboratory Testing
Major geographies analyzed under this research report are:
- North America
- Rest of the World
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments